GlassScriptPhysician profile
Adam D Zeitlin
NPI 1386745578
$8,218.59
in general payments reported to CMS, 2019-2025
42 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $1,048 · 2021: $1,251 · 2022: $700 · 2023: $1,281 · 2024: $1,717 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.66 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $967.60 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $864.38 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $769.11 | 2019-2024 | |
| Novo Nordisk INC | $664.05 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $427.11 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $415.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $372.53 | 2019-2025 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $329.25 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sumitomo Pharma America, INC. | $316.78 | 2023-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $303.83 | 2024-2025 | Ingrezza |
| Scilex Pharmaceuticals INC. | $279.90 | 2021-2025 | Ztlido |
| Sanofi-Aventis U.S. LLC | $277.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $225.63 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $208.42 | 2021-2025 | Zoryve, Seglentis |
| Astellas Pharma US INC | $193.87 | 2019-2023 | Myrbetriq, Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Zeitlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.